NSE / BSEHealthcare
β‚Ή6680.00-101.40-1.50%
P/E29.2Mkt Capβ‚Ή8.95 K CrEV/EBITDA0.0

PROCTER & GAMBLE HEALTH LIMITED

P/E29.2Mkt Capβ‚Ή8.95 K CrEV/EBITDA0.0
Company Profile

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
β€”
β€”
EV / Sales
β€”
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
β€”
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
β€”
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 14.25% over 1Y
Monthly Returns

Historically, May has averaged the highest return (+5.1%); Mar the lowest (-3.8%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-7.0%Negative MonthJan 2026: -7.03%-7.3%Negative MonthFeb 2026: -7.34%-2.3%Negative MonthMar 2026: -2.30%+8.3%Positive MonthApr 2026: +8.26%+7.1%Positive MonthMay 2026: +7.06%+13.8%Positive MonthJun 2026: +13.79%+5.6%*Positive MonthJul 2026: +5.55%β€”β€”β€”β€”β€”
2025+2.8%Positive MonthJan 2025: +2.80%-7.3%Negative MonthFeb 2025: -7.30%+3.0%Positive MonthMar 2025: +3.02%-1.4%Neutral MonthApr 2025: -1.35%+13.9%Positive MonthMay 2025: +13.86%+1.8%Neutral MonthJun 2025: +1.78%+0.4%Neutral MonthJul 2025: +0.35%+7.9%Positive MonthAug 2025: +7.87%-0.8%Neutral MonthSep 2025: -0.83%-2.2%Negative MonthOct 2025: -2.17%-7.2%Negative MonthNov 2025: -7.21%-0.5%Neutral MonthDec 2025: -0.49%
2024+3.7%Positive MonthJan 2024: +3.75%-0.9%Neutral MonthFeb 2024: -0.88%-7.5%Negative MonthMar 2024: -7.47%+4.5%Positive MonthApr 2024: +4.46%-4.0%Negative MonthMay 2024: -4.03%+7.0%Positive MonthJun 2024: +7.02%+4.0%Positive MonthJul 2024: +4.04%-1.1%Neutral MonthAug 2024: -1.09%+4.5%Positive MonthSep 2024: +4.46%-3.6%Negative MonthOct 2024: -3.58%-0.8%Neutral MonthNov 2024: -0.85%+0.9%Neutral MonthDec 2024: +0.92%
2023+1.9%Neutral MonthJan 2023: +1.85%+14.1%Positive MonthFeb 2023: +14.12%+0.1%Neutral MonthMar 2023: +0.11%-0.4%Neutral MonthApr 2023: -0.41%+12.5%Positive MonthMay 2023: +12.51%+0.2%Neutral MonthJun 2023: +0.23%+1.1%Neutral MonthJul 2023: +1.07%-8.1%Negative MonthAug 2023: -8.08%+4.8%Positive MonthSep 2023: +4.84%-0.2%Neutral MonthOct 2023: -0.24%+0.9%Neutral MonthNov 2023: +0.89%-3.9%Negative MonthDec 2023: -3.88%
2022-4.6%Negative MonthJan 2022: -4.59%-9.4%Negative MonthFeb 2022: -9.45%-12.4%Negative MonthMar 2022: -12.45%+10.8%Positive MonthApr 2022: +10.76%-4.0%Negative MonthMay 2022: -3.95%-1.7%Neutral MonthJun 2022: -1.75%+6.2%Positive MonthJul 2022: +6.23%-5.4%Negative MonthAug 2022: -5.44%-2.8%Negative MonthSep 2022: -2.76%-1.3%Neutral MonthOct 2022: -1.26%+2.6%Positive MonthNov 2022: +2.59%-3.0%Negative MonthDec 2022: -3.04%
2021β€”β€”β€”β€”β€”-5.4%Negative MonthJun 2021: -5.36%-4.3%Negative MonthJul 2021: -4.25%+1.5%Neutral MonthAug 2021: +1.47%-0.4%Neutral MonthSep 2021: -0.37%+0.2%Neutral MonthOct 2021: +0.18%-1.9%Neutral MonthNov 2021: -1.89%-0.5%Neutral MonthDec 2021: -0.49%
AvgΒ±SD-0.6%Β±4.3%-2.2%Β±8.6%-3.8%Β±5.5%+4.3%Β±4.7%+5.1%Β±7.8%+2.6%Β±6.2%+2.2%Β±3.6%-1.1%Β±5.6%+1.1%Β±3.0%-1.4%Β±1.4%-1.3%Β±3.3%-1.4%Β±1.8%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.172x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ€”
EBITDA Growthβ€”
Net Profitβ€”
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–² 71.6%
Revenue CAGR 5Y0.0%
EBITDA CAGR 5Y0.0%
Net Profit CAGR 5Y0.0%
NP Growth 1Y0.0%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β€”β€”β€”β€”β€”β€”β€”β€”
Mar 2024β‚Ή1.15 K Crβ€”β‚Ή201.00 Crβ€”β€”β€”-6.4%-12.2%
Mar 2023β‚Ή1.23 K Crβ€”β‚Ή229.00 Crβ€”β€”β€”10.4%18.7%
Mar 2022β‚Ή1.11 K Crβ€”β‚Ή193.00 Crβ€”β€”β€”10.4%9.0%
Mar 2021β‚Ή1.01 K Crβ€”β‚Ή177.00 Crβ€”β€”β€”-25.6%-30.3%
Mar 2020β€”β€”β€”β€”β€”β€”β€”β€”
Mar 2019β‚Ή927.00 Crβ€”β‚Ή159.00 Crβ€”β€”β€”9.2%-81.0%
Mar 2018β‚Ή849.00 Crβ€”β‚Ή839.00 Crβ€”β€”β€”21.6%792.6%
Mar 2017β‚Ή698.00 Crβ€”β‚Ή94.00 Crβ€”β€”β€”-29.7%19.0%
Mar 2016β‚Ή993.00 Crβ€”β‚Ή79.00 Crβ€”β€”β€”5.6%46.3%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020 18mJun 2021Jun 2022Jun 2023Jun 2024Mar 2025 16mTTM
Revenue / Net Sales8679409936988499271,3561,0091,1141,2301,1519341,349
Total Expenses8098558776217017231,037762846905845616947
EBIT / Operating Profit598511677148204319246268325307319402
OPM %791211172224242426273430
Other Income202224747684866181318-51016
Finance Costs0000000101100
Depreciation & Amortisation13232519211729302728271723
Profit Before Tax6783115132895234355233253314273312395
Tax %35363129632282424272625-
Net Profit / PAT43547994839159254177193229201234293
EPS (β‚Ή)26.0432.2747.6756.57505.2795.64153.07106.51115.98138.24121.08141.22176.81
Dividend Payout %23232327870150122456921589-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
PROCTER & GAMBLE HEALTH LIMITEDthis co.β‚Ή8.95 K Crβ‚Ή934.00 Cr29.2014.440.00-18.9%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of PROCTER & GAMBLE HEALTH LIMITED and the metrics that matter.

Browse the full Equiscale Academy